Discussions with Acerta Pharma BV

Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.

The Company will make a further announcement if and when appropriate.

– ENDS –

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra   Erkal-Paler	UK/Global	+44 20 7604 8030
Neil   Burrows	UK/Global	+44 20 7604 8032
Vanessa   Rhodes	UK/Global	+44 20 7604 8037
Karen   Birmingham	UK/Global	+44 20 7604 8120
Jacob   Lund	Sweden	+46   8 553 260 20
Michele   Meixell	US	+1 302   885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen	Oncology	+44 7818 524185
Eugenia   Litz	RIA	+44 7884 735627
Nick Stone	CVMD	+44 7717 618834
Craig   Marks	Finance	+44 7881   615764
Christer   Gruvris	Consensus   Forecasts	+44 7827 836825
US
Lindsey   Trickett	Oncology, ING	+1 240 543 7970
Mitch   Chan	Oncology	+1 240 477 3771
Dial /   Toll-Free		+1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF SECURITIES.